Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 9/20 | 0.50 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 2/20 | 0.40 |
| ▸ | F7 | P08709 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | F3 | P13726 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31416308 | 1.00 | RHEB (0.50) | RHEBDRD4DRD3SIRT2DRD2 | |
| Acetic Acid SCHEMBL27942674 | 0.87 | RHEB (0.45) | RHEBSIRT2P2RX7 | |
| Ethoxycarbonyl Group SCHEMBL27479240 | 0.79 | RHEB (0.39) | RHEBDRD4DRD3SIRT2DRD2 | |
| SCHEMBL7448671 | 0.77 | RHEB (0.47) | RHEBDRD4DRD3DRD2AHR | |
| SCHEMBL1065531 | 0.77 | AHR (0.52) | RHEBAHRF7LTA4HF3 | |
| SCHEMBL25252534 | 0.77 | RHEB (0.47) | RHEBDRD4DRD3DRD2AHR | |
| SCHEMBL2503153 | 0.77 | RHEB (0.40) | RHEBAHRF7LTA4HF3 | |
| SCHEMBL8528766 | 0.77 | RHEB (0.40) | RHEBAHRF7LTA4HF3 | |
| SCHEMBL30774212 | 0.77 | RHEB (0.47) | RHEBDRD4DRD3DRD2AHR | |
| SCHEMBL28906650 | 0.77 | RHEB (0.40) | RHEBAHRF7LTA4HF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3596089-B1 | ANTIBACTERIAL COMPOUNDS | UNIV NOTTINGHAM (GB) | 2023-12-06 | — | — | EP | disclosed |
| US-11192888-B2 | Antibacterial compounds | THE UNIVERSITY OF NOTTINGHAM (GB) | 2021-12-07 | — | — | US | disclosed |
| US-20200199118-A1 | ANTIBACTERIAL COMPOUNDS | THE UNIVERSITY OF NOTTINGHAM (GB) | 2020-06-25 | — | — | US | disclosed |
| WO-2020061470-A1 | NOVEL QUINAZOLINE EGFR INHIBITORS | SPECTRUM PHARMACEUTICALS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| WO-2018167506-A1 | ANTIBACTERIAL COMPOUNDS | THE UNIVERSITY OF NOTTINGHAM (GB) | 2018-09-20 | — | — | WO | disclosed |
| EP-2197842-B1 | 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORP (US) | 2012-05-23 | — | — | EP | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
| EP-2197842-A1 | 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009032116-A1 | 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| US-5834494-A | SEROTONIN 5HT2B/2C RECEPTOR ANTAGONISTS; CNS NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS; IRRITABLE BOWEL SYNDROME | SMITHKLINE BEECHAM P.L.C. (GB) | 1998-11-10 | — | — | US | disclosed |
| EP-0707581-B1 | INDOLINE DERIVATIVES AS 5HT2C ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-02-26 | — | — | EP | disclosed |
| CN-1129937-A | Indoline derivatives as 5HT2C antagonists | SMITHKLINE BEECHAM PLC (GB) | 1996-08-28 | — | — | CN | disclosed |
| EP-0707581-A1 | INDOLINE DERIVATIVES AS 5HT 2C? ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995001976-A1 | INDOLINE DERIVATIVES AS 5HT2C ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-01-19 | — | — | WO | disclosed |
| US-4101583-A | Alpha-methylthio-alpha-(2-aminophenyl) acetaldehyde diloweralkyl acetals | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1978-07-18 | — | — | US | disclosed |
| US-4080341-A | Carbazolenine and indole compounds | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1978-03-21 | — | — | US | disclosed |
| US-4067875-A | Certain N-phenyl or N-pyridyl aza sulfonium salts | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1978-01-10 | — | — | US | disclosed |
| US-3992392-A | Synthesis of indoles from anilines and intermediates therein | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1976-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | RHEB 2655/4885DRD4 499/4885DRD3 382/4885 |
| US-11192888-B2 | Antibacterial compounds | CFTR, CLPP, MRPL21 | RHEB 2107/4885DRD4 1043/4885DRD3 2018/4885 |
| US-20200199118-A1 | ANTIBACTERIAL COMPOUNDS | CFTR, CLPP, MRPL21 | RHEB 2107/4885DRD4 1043/4885DRD3 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.